Boule Diagnostics
Boule Diagnostics - ESG profile (ABG Sundal Collier)
2019-09-11 18:43
Strict regulations concerning product quality and safety
As a global diagnostics company, Boule Diagnostics is responsible for controlling risks regarding product quality and safety. In addition to internal control requirements, the company sees the importance of monitoring its value chain. Some of Boule’s 200-plus suppliers operate in areas where they might risk breaching environmental standards, business ethics, human rights, and working conditions. Boule is approved within the parameters of the EU regulation frameworks REACH, RoHS and WEEE. The company must continuously meet regulations defined by government agencies, such as the US FDA, in the markets it operates in. In Oct. 2018, Boule Diagnostics received a warning letter from the FDA about deficiencies in documenting internal procedures. The company has since made further efforts in improving its quality control system processes, and has given its action plan the highest priority.
Values the UN Global Compact initiative
The company continuously contributes to the protection of human rights, labour, the environment and anti-corruption, which all are vital parts of its code of conduct. Boule’s efforts are applicable to both its own workforce and to several parties in the value chain. The company educates its employees, which also involves maintaining safety standards to minimise the risk of physical injury. According to management, Boule continuously works to adhere to the ten principles of the UN Global Compact initiative. Transportation is the company’s biggest source of carbon emissions, but by ensuring that all its shipments are guided by an environmental policy, it aims to reduce its carbon footprint.
As a global diagnostics company, Boule Diagnostics is responsible for controlling risks regarding product quality and safety. In addition to internal control requirements, the company sees the importance of monitoring its value chain. Some of Boule’s 200-plus suppliers operate in areas where they might risk breaching environmental standards, business ethics, human rights, and working conditions. Boule is approved within the parameters of the EU regulation frameworks REACH, RoHS and WEEE. The company must continuously meet regulations defined by government agencies, such as the US FDA, in the markets it operates in. In Oct. 2018, Boule Diagnostics received a warning letter from the FDA about deficiencies in documenting internal procedures. The company has since made further efforts in improving its quality control system processes, and has given its action plan the highest priority.
Values the UN Global Compact initiative
The company continuously contributes to the protection of human rights, labour, the environment and anti-corruption, which all are vital parts of its code of conduct. Boule’s efforts are applicable to both its own workforce and to several parties in the value chain. The company educates its employees, which also involves maintaining safety standards to minimise the risk of physical injury. According to management, Boule continuously works to adhere to the ten principles of the UN Global Compact initiative. Transportation is the company’s biggest source of carbon emissions, but by ensuring that all its shipments are guided by an environmental policy, it aims to reduce its carbon footprint.
- Läs mer på Introduce
Läsaren av innehållet kan anta att ABG Sundal Collier har erhållit eller kommer att erhålla betalning för utförandet av finansiella företagstjänster från bolaget. Ersättningen är på förhand avtalad och är inte beroende av innehållet.
info@introduce.se (Introduce.se)
ABG Sundal Collier - Introduce.se